•
Mar 30, 2024

Waters Q1 2024 Earnings Report

Waters' Q1 2024 financial performance was reported, with sales at the high end of guidance and EPS exceeding expectations.

Key Takeaways

Waters Corporation reported Q1 2024 sales of $637 million, a 7% decrease compared to Q1 2023. GAAP EPS was $1.72, and non-GAAP EPS was $2.21. The company maintained its full-year guidance.

Sales of $637 million were at the high-end of guidance, but declined 7% as reported and 9% in organic constant currency.

GAAP EPS was $1.72, with non-GAAP EPS at $2.21, both exceeding guidance.

Gross margin and adjusted operating margin expanded due to operational excellence.

Operating cash flow was strong at $263 million, with free cash flow of $234 million, representing 37% of sales.

Total Revenue
$637M
Previous year: $685M
-7.0%
EPS
$2.21
Previous year: $2.49
-11.2%
Pharma Market Sales
-3%
Previous year: 384,898,000%
-100.0%
Industrial Market Sales
-7%
Previous year: 209,650,000%
-100.0%
Academic & Gov Sales
-25%
Previous year: 90,126,000%
-100.0%
Gross Profit
$363M
Previous year: $400M
-9.3%
Cash and Equivalents
$338M
Previous year: $486K
+69481.1%
Free Cash Flow
$234M
Total Assets
$4.51B
Previous year: $3.31B
+36.4%

Waters

Waters

Waters Revenue by Geographic Location

Forward Guidance

The Company expects second quarter 2024 organic constant currency sales growth to be in the range of -6.0% to -4.0%. The Company expects full-year 2024 organic constant currency sales growth to be in the range of -0.5% to +1.5%.

Revenue & Expenses

Visualization of income flow from segment revenue to net income